2026 Top 7 Equine Systemic Injectable Broad-Spectrum Antibiotics in Canada

Excenel RTU EZ is a ready-to-use ceftiofur formulation favored in equine practice for reliable beta-lactam broad-spectrum coverage and the convenience of a pre-mixed injectable. It earns a best-in-class position for combining strong activity against common equine pathogens with reduced preparation time and lower waste compared with multi-component generics, though its acquisition cost is typically higher than basic tetracyclines.

Pendi-Strep is an established penicillin-plus-streptomycin combination valued in equine practice for reliable coverage of many gram-positive and some gram-negative pathogens and a low acquisition cost. It earns a top position here because it is often the most cost-effective systemic injectable choice for common equine infections, though it lacks the concentrated gram-negative punch of gentamicin and the long-acting, single-dose convenience of macrolides like Draxxin. Compared with Trivetrin, Pendi-Strep is generally preferred when strong beta-lactam activity is required and when budget constraints drive treatment decisions.

Borgal is a high-potency fluoroquinolone injectable known for excellent gram-negative activity and superior tissue penetration, used when rapid, robust antimicrobial action is needed in equine systemic infections. As a market leader for potent, targeted therapy it typically commands a premium price relative to aminoglycosides and tetracyclines, but provides technical advantages in pharmacokinetics and clinical efficacy for severe or refractory cases.

Baytril 100 is a widely used enrofloxacin injectable recognized for broad-spectrum activity, excellent tissue penetration, and an extensive clinical track record in equine medicine. It competes directly with other fluoroquinolones like Borgal on technical performance, and as a global brand it often provides advantages in regulatory availability and supply-chain reliability that can translate to more consistent pricing and access for veterinary practices.

Trivetrin (a broad-spectrum trimethoprim–sulfonamide style regimen) is positioned for versatile systemic coverage against a wide range of bacterial species, offering a balance of spectrum and cost that makes it attractive for many equine indications. It stands out relative to Pendi-Strep by providing broader activity against some atypical and intracellular organisms and is often less nephrotoxic than aminoglycosides like Gentocin, while being more affordable than long-acting macrolides such as Draxxin. For clinicians seeking a middle-ground injectable with broad coverage and favorable economics, Trivetrin is a practical choice.

Gentocin Injectable (gentamicin sulfate) is a market leader for potent gram-negative bactericidal activity and is widely used in equine practice for severe or mixed infections, particularly when combination therapy with a beta-lactam is indicated. Its technical advantage is rapid, high-level bactericidal effect against many enteric and hospital-acquired gram-negatives, but this comes with higher monitoring needs and nephrotoxicity risk compared with Pendi-Strep and Trivetrin, and it does not offer the prolonged dosing interval provided by Draxxin. Economically, Gentocin can drive higher ancillary costs (monitoring, fluid support), so it is typically reserved for cases where its superior gram-negative coverage is essential.